Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review
Tóm tắt
Caudate lobe liver metastases occur commonly in patients with neuroendocrine tumors. It is unknown, however, how these lesions respond to regional therapy and how their presence impacts outcomes. We reviewed our experience treating these lesions using transarterial chemoembolization (TACE). We reviewed radiographic response to TACE in 86 patients with metastatic neuroendocrine tumors to the liver. We determined the impact of caudate lesions on outcomes in comparison to the cohort of patients without caudate lesions, as well as response of caudate lesions to TACE versus lesions elsewhere in the liver. Caudate lesions were identified in 45 (52%) patients. All patients had disease in other liver segments. Only seven caudate lesions (12.3%) had a radiographic response to TACE, whereas 82% of lesions elsewhere in the liver demonstrated a response. The presence or absence of a caudate lesion did not impact the overall radiographic (82.2% vs. 82.9%), symptomatic (64.4% vs. 56.1%), or biochemical (97.6% vs. 88.9%) response to TACE (P > 0.1 for all). However, median overall survival was reduced in those presenting with caudate lesions (87.1 vs. 45.6 months, P = 0.031). Metastatic neuroendocrine tumors to the caudate lobe respond poorly to TACE. Symptomatic or threatening caudate lobe lesions should be considered for palliative resection in spite of additional inoperable liver metastases.
Tài liệu tham khảo
Berge T, Linell F. Carcinoid tumors: frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand. 1976;84:322–30.
Pommier R. The role of surgery and chemoembolization in the management of carcinoid. Presented at: California Carcinoid Fighters Conference. 2003.
Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:v1–16.
Ruszniewsi P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62 suppl 1:79–83.
Abdel-Misih SR, Bloomston M. Liver anatomy. Surg Clin North Am. 2010;90:643–53.
Hawkins W, Dematteo R, Cohen MS, Jarnagin WR, Fong Y, Angelica D’, et al. Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Chem Soc. 2005;200:345–52.
Khan AZ, Wong HZ, Malik HZ, Stiff GM, Prasad KR, Lodge JP, et al. The impact of caudate lobe involvement after hepatic resection for colorectal metastases. EJSO. 2009;35:510–4.
Abdalla E, Ribero D, Pawlik T, Zorzi D, Curley SA, Muratore A, et al. Resection of hepatic colorectal metastases involving the caudate lobe: perioperative outcome and survival. J Gastrointest Surg. 2007;11:66–72.
Abdalla EK, Vauthey JN, Couinaud C. The caudate lobe of the liver: implications of embryology and anatomy for surgery. Surg Oncol Clin N Am. 2002;11:835–48.
Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointestinal Surg. 2007;11:264–71.
Therasse P, Arbuck SG, Eisenhaeur EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
Desai DC, O’Dorisio TM, Schirmer WJ, Jung SS, Khabiri H, Villanueva V, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113–7.
Moertel CG. Karnofsky Memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1503–22.
Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003;10:483–6.
Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72–8.
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variable affecting response rates and survival. Cancer. 2005;104:1590–602.
Scherübl H. Tumor biology and prognosis of gastrointestinal carcinoids. J Clin Oncol. 2008;26:6012–3.
Kress O, Wagner R, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization for advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion. 2003;68:94–101.
Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261–7.
Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol. 1995;60:116–21.
Oberg K. The ultimate biochemical diagnosis of gastro-entero-pancreatic tumours. Digestion. 1996;57:45–7.
Kimura N, Funakoshi A, Aunis D, Miura W, Nagura H. Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A-derived bioactive peptides, in normal and neoplastic neuroendocrine tissues. Endocr Path. 1995;6:35–43.
van Persijn van Meerten EL, Gelderblum H, Bloem JL. RECIST revisited: implications for the radiologist. Eur Rad. 2010;20:1456–67.
Norlén O, Stålberg P, Oberg K, Eriksson J, Hedberg J, Hessman, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36:1419–31.
Elias D, David A, Sourrouille I, Honore C, Golere D, Dumont F, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery. 2014;155:5–12.
Norlén O, Edfeldt K, Akerstrom G, Westin G, Hellman P, Bjorklund P, et al. Peritoneal carcinomatosis from small intestinal neuroendocrine tumors: clinical course and genetic profiling. Surgery. 2014;156:1512–21.